Want to see RNLXY full AI Analyst Report?
Top Page
Rating:―N/A
Price Target:―
Action:N/A
Date:―
No summary available
Positive Factors
Innovative Product Offering
Renalytix's use of machine learning in diagnostics positions it as a leader in innovative kidney disease management, potentially driving long-term growth.
Negative Factors
Financial Distress
Ongoing financial distress with negative equity and losses threatens long-term viability, requiring urgent strategic restructuring for recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Innovative Product Offering
Renalytix's use of machine learning in diagnostics positions it as a leader in innovative kidney disease management, potentially driving long-term growth.
Read all positive factors
Renalytix (RNLXY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$50.44M
Dividend YieldN/A
Average Volume (3M)3.40K
Price to Earnings (P/E)―
Beta (1Y)0.90
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees60
SectorHealthcare
Sector Strength45
IndustryHealthcare Providers & Services
Share Statistics
EPS (TTM)-1.05
Shares Outstanding12,076,613
10 Day Avg. Volume1,284
30 Day Avg. Volume3,396
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12
Revenue Forecast (FY)$114.30M
Renalytix Business Overview & Revenue Model
Company Description
Renalytix AI PLC is a developer of artificial intelligence-enabled clinical decision support solutions for kidney disease and costly chronic medical conditions globally. The company's solutions are being designed to make significant improvements i...
How the Company Makes Money
Renalytix generates revenue primarily through the sale of its diagnostic products and services to healthcare providers, hospitals, and clinical laboratories. The company's flagship product, KidneyIntelX, is a diagnostic platform that uses machine ...
Renalytix Earnings Call Summary
Earnings Call Date:Mar 18, 2025
(Q2-2025)
| Next Earnings Date:Nov 03, 2026
Earnings Call Sentiment Positive
The earnings call presented a positive outlook for Renalytix, with significant achievements in FDA approval, Medicare reimbursement, and revenue growth. Operational improvements and strategic partnerships further enhance their position. However, resource constraints and initial market dependency present challenges. Overall, the positive developments and growth potential outweigh the challenges.Positive Updates
FDA Approval and Medicare Reimbursement
Renalytix's KidneyIntelX test received FDA approval, becoming the first-ever FDA-approved breakthrough designation prognostic test for kidney disease. It is fully Medicare reimbursed at $950 per test.
Negative Updates
Small Team and Resource Limitations
The company is constrained by a small team of eight salespeople, which affects their ability to rapidly expand and scale operations.
Read all updates
Q2-2025 Updates
Positive
Negative
FDA Approval and Medicare Reimbursement
Renalytix's KidneyIntelX test received FDA approval, becoming the first-ever FDA-approved breakthrough designation prognostic test for kidney disease. It is fully Medicare reimbursed at $950 per test.
Read all positive updates
Company Guidance
During the Renalytix Investor Presentation, several key metrics and strategic goals were outlined. The company has achieved a 20% quarter-on-quarter revenue growth, with expectations to reach $3.2 million in revenue for the fiscal year, $8.4 million the following year, and $17 million subsequently. The commercial testing volume increased from 60% to 82%, with Medicare reimbursing $950 per test. Renalytix has reduced administrative fees by 50% and decreased order cancellation rates from 24% to 8%. It also improved test turnaround time to under seven days and reduced billing to insurance payment time by 65%. Additionally, Renalytix aims for a 1% U.S. market penetration, equivalent to 150,000 tests annually. The company is focusing on expanding insurance partnerships, with 52% of testing now Medicare and Medicare Advantage patients, and is investing in strategic partnerships, including with pharma companies, to enhance its competitive positioning.Renalytix Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Renalytix Technical Analysis
Positive
―
Price Trends
2.85
Positive
2.10
Positive
2.52
Positive
Market Momentum
0.41
Positive
66.65
Neutral
54.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNLXY, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 3.70, equal to the 50-day MA of 2.85, and equal to the 200-day MA of 2.52, indicating a bullish trend. The MACD of 0.41 indicates Positive momentum. The RSI at 66.65 is Neutral, neither overbought nor oversold. The STOCH value of 54.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RNLXY.
Renalytix Risk Analysis
Renalytix disclosed 91 risk factors in its most recent earnings report. Renalytix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
Renalytix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―